These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32233172)

  • 41. Increasing levels of minimum inhibitory concentration vancomycin in methicillin resistant Staphylococcus aureus alarming bell for vancomycin abusers?
    Veer P; Chande C; Chavan S; Wabale V; Chopdekar K; Bade J; Joshi A
    Indian J Med Microbiol; 2010; 28(4):413-4. PubMed ID: 20966589
    [No Abstract]   [Full Text] [Related]  

  • 42. [Impact of vancomycin minimum inhibitory concentration or inadequate therapeutic management in the clinical outcome failure due to methicillin-resistant Staphylococcus aureus?].
    González-Abad MJ; Alonso Sanz M
    An Pediatr (Barc); 2015 May; 82(5):373-4. PubMed ID: 25205179
    [No Abstract]   [Full Text] [Related]  

  • 43. Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest® macromethod among patients with MRSA bloodstream infections: a pilot study.
    Martirosov DM; Bidell MR; Pai MP; Scheetz MH; Rosenkranz SL; Faragon C; Malik M; Mendes RE; Jones RN; McNutt LA; Lodise TP
    BMC Infect Dis; 2017 Aug; 17(1):534. PubMed ID: 28764660
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.
    Moise-Broder PA; Forrest A; Birmingham MC; Schentag JJ
    Clin Pharmacokinet; 2004; 43(13):925-42. PubMed ID: 15509186
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics/pharmacodynamics of antofloxacin hydrochloride in a neutropenic murine thigh model of Staphylococcus aureus infection.
    Xiao XM; Xiao YH
    Acta Pharmacol Sin; 2008 Oct; 29(10):1253-60. PubMed ID: 18817632
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vivo efficacy and pharmacological properties of a novel glycopeptide (YV4465) against vancomycin-intermediate Staphylococcus aureus.
    Yarlagadda V; Konai MM; Paramanandham K; Nimita VC; Shome BR; Haldar J
    Int J Antimicrob Agents; 2015 Oct; 46(4):446-50. PubMed ID: 26188396
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recent Updates on the Role of Pharmacokinetics-pharmacodynamics in Antimicrobial Susceptibility Testing as Applied to Clinical Practice.
    Labreche MJ; Graber CJ; Nguyen HM
    Clin Infect Dis; 2015 Nov; 61(9):1446-52. PubMed ID: 26105168
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
    Jacqueline C; Caillon J; Le Mabecque V; Miègeville AF; Hamel A; Bugnon D; Ge JY; Potel G
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3397-400. PubMed ID: 17591849
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia.
    Song KH; Kim HB; Kim HS; Lee MJ; Jung Y; Kim G; Hwang JH; Kim NH; Kim M; Kim CJ; Choe PG; Chung JY; Park WB; Kim ES; Park KU; Kim NJ; Kim EC; Oh MD
    Int J Antimicrob Agents; 2015 Dec; 46(6):689-95. PubMed ID: 26555059
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus.
    Murillo O; Doménech A; Garcia A; Tubau F; Cabellos C; Gudiol F; Ariza J
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4011-7. PubMed ID: 17015630
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model.
    Dandekar PK; Tessier PR; Williams P; Nightingale CH; Nicolau DP
    J Antimicrob Chemother; 2003 Sep; 52(3):405-11. PubMed ID: 12917254
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Potential therapeutic failure of generic vancomycin in a liver transplant patient with MRSA peritonitis and bacteremia.
    Rodriguez CA; Agudelo M; Cataño JC; Zuluaga AF; Vesga O
    J Infect; 2009 Oct; 59(4):277-80. PubMed ID: 19698745
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus.
    Salem AH; Zhanel GG; Ibrahim SA; Noreddin AM
    Clin Exp Pharmacol Physiol; 2014 Jun; 41(6):437-43. PubMed ID: 24341387
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro susceptibility of clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) to manufactured generic drugs compared with the brand vancomycin.
    Fujimura S; Watanabe A; Fuse K; Kikuchi T; Gomi K; Tokue Y
    Int J Antimicrob Agents; 2008 Apr; 31(4):391-2. PubMed ID: 18308516
    [No Abstract]   [Full Text] [Related]  

  • 55. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.
    Rybak MJ; Le J; Lodise TP; Levine DP; Bradley JS; Liu C; Mueller BA; Pai MP; Wong-Beringer A; Rotschafer JC; Rodvold KA; Maples HD; Lomaestro BM
    Am J Health Syst Pharm; 2020 May; 77(11):835-864. PubMed ID: 32191793
    [No Abstract]   [Full Text] [Related]  

  • 56. Efficacy of tigecycline alone and with rifampin in foreign-body infection by methicillin-resistant Staphylococcus aureus.
    Garrigós C; Murillo O; Euba G; Verdaguer R; Tubau F; Cabellos C; Cabo J; Ariza J
    J Infect; 2011 Sep; 63(3):229-35. PubMed ID: 21763722
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapeutic effect of ME1036 on endocarditis experimentally induced by methicillin-resistant Staphylococcus aureus.
    Nagura J; Kijima K; Kurazono M; Takahata S; Sugano T; Tanaka Y; Hirai Y; Yamada K; Takayama Y; Shitara E; Yonezawa M
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3526-8. PubMed ID: 16048975
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of clinical outcome in children and adolescents receiving vancomycin for invasive infections due to methicillin-resistant Staphylococcus aureus: impact of increasing vancomycin MICs.
    Arun A; Swamy S; Jacob K; Sharma R; Kohlhoff SA; Hammerschlag MR
    Minerva Pediatr; 2018 Jun; 70(3):207-211. PubMed ID: 28006894
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model.
    Lepak AJ; Andes DR
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4764-9. PubMed ID: 27216072
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Investigation of reduced vancomycin susceptibility in methicillin-resistant staphylococci].
    Kuşcu F; Oztürk DB; Gürbüz Y; Tütüncü EE; Sencan I; Gül S
    Mikrobiyol Bul; 2011 Apr; 45(2):248-57. PubMed ID: 21644067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.